Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises. Local targets link to admitted publications; unresolved targets remain external evidence.
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
10.1038/s41564-020-0695-z · 2020 · External reference
10.1016/j.it.2020.10.004
10.1016/j.it.2020.10.004 · External reference
10.1016/j.cell.2020.02.052
10.1016/j.cell.2020.02.052 · External reference
10.1016/j.cell.2020.04.011
10.1016/j.cell.2020.04.011 · External reference
10.1016/s0140-6736(20)30251-8
10.1016/s0140-6736(20)30251-8 · External reference
10.1038/s41586-020-2012-7
10.1038/s41586-020-2012-7 · External reference
10.1021/acs.jmedchem.0c00606
10.1021/acs.jmedchem.0c00606 · External reference
10.1021/acsinfecdis.0c00701
10.1021/acsinfecdis.0c00701 · External reference
10.1111/cei.13087
10.1111/cei.13087 · External reference
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
2020 · External reference
10.1016/s0140-6736(20)30183-5
10.1016/s0140-6736(20)30183-5 · External reference
10.1016/j.smim.2013.11.002
10.1016/j.smim.2013.11.002 · External reference
10.2217/imt-2016-0020
10.2217/imt-2016-0020 · External reference
10.1016/j.ijantimicag.2020.105954
10.1016/j.ijantimicag.2020.105954 · External reference
Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection
10.3389/fimmu.2020.01022 · 2020 · External reference
10.1038/s41572-019-0069-0
10.1038/s41572-019-0069-0 · External reference
Cytokine release syndrome in severe COVID-19
10.1126/science.abb8925 · 2020 · External reference
10.1016/j.csbj.2021.01.034 · Admitted local publication
Could PROTACs Protect Us From COVID-19?
10.1016/j.drudis.2020.08.007 · 2020 · External reference
Molecular targets and system biology approaches for drug repurposing against SARS-CoV-2
10.1186/s42269-020-00444-3 · 2020 · External reference
10.1002/ange.202008835
10.1002/ange.202008835 · External reference
The SARS-coronavirus infection cycle: A survey of viral membrane proteins, their functional interactions and pathogenesis
2021 · External reference
10.1038/s41591-020-01227-z
10.1038/s41591-020-01227-z · External reference
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
10.1016/j.jiph.2020.07.013 · 2020 · External reference
10.1039/c7cs00536a
10.1039/c7cs00536a · External reference
10.1208/s12248-014-9687-3
10.1208/s12248-014-9687-3 · External reference
10.1016/j.drudis.2014.10.003
10.1016/j.drudis.2014.10.003 · External reference
10.1021/acs.jmedchem.7b00318
10.1021/acs.jmedchem.7b00318 · External reference
Proteolysis targeting chimera (PROTAC): A paradigm-shifting approach in small molecule drug discovery
10.2174/1568026618666181010101922 · 2018 · External reference
Unresolved reference
2021 · External reference
10.1007/s11030-020-10134-x
10.1007/s11030-020-10134-x · External reference
Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery
10.1021/acs.jcim.0c00113 · 2020 · External reference
Aprotinin Inhibits SARS-CoV-2 Replication
10.3390/cells9112377 · 2020 · External reference
10.1038/nrd.2017.227
10.1038/nrd.2017.227 · External reference
The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies
10.3390/cells9112343 · 2020 · External reference
10.1016/j.smim.2020.101427
10.1016/j.smim.2020.101427 · External reference
Instability of therapeutic proteins - An overview of stresses, stabilization mechanisms and analytical techniques involved in lyophilized proteins
10.1016/j.ijbiomac.2020.11.188 · 2021 · External reference
10.1073/pnas.2016093117
10.1073/pnas.2016093117 · External reference
Immunomodulatory therapeutic proteins in COVID-19: current clinical development and clinical pharmacology considerations
10.1002/jcph.1729 · 2020 · External reference
Challenges and advancements in the pharmacokinetic enhancement of therapeutic proteins
2021 · External reference
10.1007/s11095-019-2689-1
10.1007/s11095-019-2689-1 · External reference
Key physicochemical characteristics influencing adme properties of therapeutic proteins
10.1007/978-981-13-7709-9_6 · 2019 · External reference
Chemical and physical instabilities in manufacturing and storage of therapeutic proteins
10.1016/j.copbio.2019.01.014 · 2019 · External reference
10.1016/j.tibtech.2018.05.008
10.1016/j.tibtech.2018.05.008 · External reference
10.1016/j.xphs.2018.11.029
10.1016/j.xphs.2018.11.029 · External reference
10.1016/j.coviro.2015.03.013
10.1016/j.coviro.2015.03.013 · External reference
10.1038/s41598-021-81749-9
10.1038/s41598-021-81749-9 · External reference
Therapeutic potential of mesenchymal stem cells and their products in lung diseases-intravenous administration versus inhalation
10.3390/pharmaceutics13020232 · 2021 · External reference
10.1002/sctm.20-0472
10.1002/sctm.20-0472 · External reference
10.1016/j.biopha.2021.111300
10.1016/j.biopha.2021.111300 · External reference
Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19?
10.1016/j.mehy.2021.110508 · 2021 · External reference
10.1080/14787210.2017.1305888
10.1080/14787210.2017.1305888 · External reference
10.1016/j.drudis.2020.06.022
10.1016/j.drudis.2020.06.022 · External reference
From Wuhan to COVID-19 pandemic: An up-to-date review of its pathogenesis, potential therapeutics, and recent advances
10.3390/microorganisms8060850 · 2020 · External reference
10.3389/fphar.2020.584881
10.3389/fphar.2020.584881 · External reference
10.1016/j.ejphar.2020.173548
10.1016/j.ejphar.2020.173548 · External reference
10.1016/j.lfs.2020.117883
10.1016/j.lfs.2020.117883 · External reference
10.1002/rmv.2174
10.1002/rmv.2174 · External reference
Therapeutic targets and potential agents for the treatment of COVID-19
10.1002/med.21776 · 2021 · External reference
10.1146/annurev-micro-020518-115759
10.1146/annurev-micro-020518-115759 · External reference
Rapid repurposing of drugs for COVID-19
10.1126/science.abb9332 · 2020 · External reference
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
10.1038/d41573-020-00016-0 · 2020 · External reference
10.1021/acs.jmedchem.0c00502
10.1021/acs.jmedchem.0c00502 · External reference
10.1111/bph.15092
10.1111/bph.15092 · External reference
Chemoinformatic analysis of psychotropic and antihistaminic drugs in the light of experimental anti-SARS-CoV-2 activities. Advances and applications in bioinformatics and chemistry
10.2147/aabc.s304649 · 2021 · External reference
10.1038/s41573-020-0087-3
10.1038/s41573-020-0087-3 · External reference
A guide to drug discovery: Target selection in drug discovery
10.1038/nrd986 · 2003 · External reference
Drugs as habitable planets in the space of dark chemical matter
10.1016/j.drudis.2017.07.003 · 2018 · External reference
Target-Pathogen: a structural bioinformatic approach to prioritize drug targets in pathogens
10.1093/nar/gkx1015 · 2018 · External reference
10.1021/acs.jcim.8b00832
10.1021/acs.jcim.8b00832 · External reference
Accelerated drug discovery by rapid candidate drug identification
10.1016/j.drudis.2019.03.026 · 2019 · External reference
Fragment-based target screening as an empirical approach to prioritising targets: a case study on antibacterials
10.1016/j.drudis.2020.09.003 · 2020 · External reference
Integration of target discovery, drug discovery and drug delivery: A review on computational strategies
10.1002/wnan.1554 · 2019 · External reference
Combining experimental strategies for successful target deconvolution
10.1016/j.drudis.2020.09.016 · 2020 · External reference
Homology modeling in drug discovery: current trends and applications
10.1016/j.drudis.2009.04.006 · 2009 · External reference
Homology modeling in drug discovery: Overview, current applications, and future perspectives
10.1111/cbdd.13388 · 2019 · External reference
10.1124/pr.112.007336
10.1124/pr.112.007336 · External reference
Ligands and receptors with broad binding capabilities have common structural characteristics: an antibiotic design perspective
10.1021/acs.jmedchem.9b00220 · 2019 · External reference
10.1016/j.ejphar.2020.173705
10.1016/j.ejphar.2020.173705 · External reference
10.1016/j.drudis.2010.05.015
10.1016/j.drudis.2010.05.015 · External reference
10.1021/acs.accounts.5b00516
10.1021/acs.accounts.5b00516 · External reference
10.1016/j.chembiol.2011.12.013
10.1016/j.chembiol.2011.12.013 · External reference
10.1093/nar/gkr825
10.1093/nar/gkr825 · External reference
10.1016/j.cbpa.2018.05.003
10.1016/j.cbpa.2018.05.003 · External reference
10.1016/j.jmb.2020.11.024
10.1016/j.jmb.2020.11.024 · External reference
Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms
10.1126/science.abe9403 · 2020 · External reference
10.1038/s41586-020-2286-9
10.1038/s41586-020-2286-9 · External reference
Interactome of SARS-CoV-2 / nCoV19 modulated host proteins with computationally predicted PPIs
2020 · External reference
H2V: a database of human genes and proteins that respond to SARS-CoV-2, SARS-CoV, and MERS-CoV infection
10.1186/s12859-020-03935-2 · 2021 · External reference
10.1016/j.drudis.2020.03.019
10.1016/j.drudis.2020.03.019 · External reference
Antiviral drug discovery: preparing for the next pandemic
2021 · External reference
Current and prospective computational approaches and challenges for developing COVID-19 vaccines
10.1016/j.addr.2021.02.004 · 2021 · External reference
10.1016/j.pbiomolbio.2015.02.006
10.1016/j.pbiomolbio.2015.02.006 · External reference
10.1002/minf.201400040
10.1002/minf.201400040 · External reference
Fr-PPIChem: An Academic Compound Library Dedicated to Protein-Protein Interactions
10.1021/acschembio.0c00179 · 2020 · External reference
Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials
10.1038/s41392-020-00315-3 · 2020 · External reference
Development of protein-protein interaction inhibitors for the treatment of infectious diseases
10.1016/bs.apcsb.2017.07.005 · 2018 · External reference
10.1038/nrd3410
10.1038/nrd3410 · External reference
10.1038/s41467-020-18709-w
10.1038/s41467-020-18709-w · External reference
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
10.1186/s13045-020-00850-0 · 2020 · External reference
SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy
10.7150/thno.48076 · 2020 · External reference
Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains
10.1007/s40121-020-00300-x · 2020 · External reference
10.1093/bib/bbaa288
10.1093/bib/bbaa288 · External reference
Repurposing sigma-1 receptor ligands for COVID-19 therapy?
10.3389/fphar.2020.582310 · 2020 · External reference
10.1021/acs.jcim.0c00179
10.1021/acs.jcim.0c00179 · External reference
10.1002/med.21728
10.1002/med.21728 · External reference
10.1016/s2589-7500(20)30192-8
10.1016/s2589-7500(20)30192-8 · External reference
Project IDentif.AI: harnessing artificial intelligence to rapidly optimize combination therapy development for infectious disease intervention
2020 · External reference
What are the odds of finding a COVID-19 drug from a lab repurposing screen?
10.1021/acs.jcim.0c00861 · 2020 · External reference
10.1016/j.bj.2020.05.001
10.1016/j.bj.2020.05.001 · External reference
10.1101/2020.06.04.135046
10.1101/2020.06.04.135046 · External reference
10.1038/s41586-020-2577-1
10.1038/s41586-020-2577-1 · External reference
In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
10.1038/s41598-020-70143-6 · 2020 · External reference
10.21203/rs.3.rs-23951/v1
10.21203/rs.3.rs-23951/v1 · External reference
10.1016/j.smim.2020.101413
10.1016/j.smim.2020.101413 · External reference
Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development
10.1016/j.dmpk.2018.11.002 · 2019 · External reference
10.1007/s40475-020-00201-6
10.1007/s40475-020-00201-6 · External reference
Keeping track of the SARS-CoV-2 vaccine pipeline
10.1038/s41577-020-00455-1 · 2020 · External reference
10.1016/j.bbrc.2020.10.012
10.1016/j.bbrc.2020.10.012 · External reference
10.1038/s41467-020-20465-w
10.1038/s41467-020-20465-w · External reference
10.4049/jimmunol.1701722
10.4049/jimmunol.1701722 · External reference
10.1021/acs.jpclett.0c02706
10.1021/acs.jpclett.0c02706 · External reference
SARS-CoV-2 nsp1: Bioinformatics, Potential Structural and Functional Features, and Implications for Drug/Vaccine Designs
10.3389/fmicb.2020.587317 · 2020 · External reference
COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning
10.3389/fimmu.2020.01581 · 2020 · External reference
10.1016/j.addr.2021.01.007
10.1016/j.addr.2021.01.007 · External reference
10.1080/14760584.2020.1825951
10.1080/14760584.2020.1825951 · External reference
10.1016/j.abb.2020.108730
10.1016/j.abb.2020.108730 · External reference
10.1016/j.mayocp.2020.11.024
10.1016/j.mayocp.2020.11.024 · External reference
Molecular Dynamics Simulation Techniques as Tools in Drug Discovery and Pharmacology: A Focus on Allosteric Drugs
10.1007/978-1-0716-1154-8_14 · 2021 · External reference
10.1016/j.tips.2020.10.005
10.1016/j.tips.2020.10.005 · External reference
Cheminformatics in Natural Product-based Drug Discovery
10.1002/minf.202000171 · 2020 · External reference
New Perspectives of Machine Learning in Drug Discovery
2020 · External reference
Drug2ways: Reasoning over causal paths in biological networks for drug discovery
10.1371/journal.pcbi.1008464 · 2020 · External reference
Merging Ligand-Based and Structure-Based Methods in Drug Discovery: An Overview of Combined Virtual Screening Approaches
2020 · External reference
10.1021/acscentsci.0c00229
10.1021/acscentsci.0c00229 · External reference
Generative topographic mapping in drug design
10.1016/j.ddtec.2020.06.003 · 2019 · External reference
10.1039/d0cs00098a
10.1039/d0cs00098a · External reference
10.1021/acs.jcim.0c00936
10.1021/acs.jcim.0c00936 · External reference
10.1016/j.drudis.2020.07.005
10.1016/j.drudis.2020.07.005 · External reference
Informatics for Chemistry, Biology, and Biomedical Sciences
10.1021/acs.jcim.0c01301 · 2021 · External reference
10.1016/j.pharmthera.2017.02.034
10.1016/j.pharmthera.2017.02.034 · External reference
10.1021/acs.chemrev.8b00728
10.1021/acs.chemrev.8b00728 · External reference
Computational strategies to combat COVID-19: useful tools to accelerate SARS-CoV-2 and coronavirus research
2020 · External reference
CoV-Seq, a New Tool for SARS-CoV-2 Genome Analysis and Visualization: Development and Usability Study
10.2196/22299 · 2020 · External reference
The impact of chemoinformatics on drug discovery in the pharmaceutical industry
10.1080/17460441.2020.1696307 · 2020 · External reference
Biomolecular Simulations in the Time of COVID19, and After
10.1109/mcse.2020.3024155 · 2020 · External reference
10.1016/j.drudis.2016.11.001
10.1016/j.drudis.2016.11.001 · External reference
10.1080/17460441.2018.1403419
10.1080/17460441.2018.1403419 · External reference
Unresolved reference
2020 · External reference
A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening
10.1016/j.isci.2020.102021 · 2021 · External reference
Ligand-Binding-Site Refinement to Generate Reliable Holo Protein Structure Conformations from Apo Structures
10.1021/acs.jcim.0c01354 · 2021 · External reference
10.1016/j.compbiomed.2020.104158
10.1016/j.compbiomed.2020.104158 · External reference
10.1371/journal.pcbi.1008449
10.1371/journal.pcbi.1008449 · External reference
10.1016/j.csbj.2020.11.029 · Admitted local publication
Selecting machine-learning scoring functions for structure-based virtual screening
10.1016/j.ddtec.2020.09.001 · 2019 · External reference
Towards gaining sight of multiscale events: utilizing network models and normal modes in hybrid methods
10.1016/j.sbi.2020.05.013 · 2020 · External reference
Accuracy or novelty: what can we gain from target-specific machine-learning-based scoring functions in virtual screening?
2021 · External reference
10.1016/j.cbi.2020.109298
10.1016/j.cbi.2020.109298 · External reference
Analysis of protein missense alterations by combining sequence- and structure-based methods
10.1002/mgg3.1166 · 2020 · External reference
Fast Rescoring Protocols to Improve the Performance of Structure-Based Virtual Screening Performed on Protein-Protein Interfaces
10.1021/acs.jcim.0c00545 · 2020 · External reference
The Art of Compiling Protein Binding Site Ensembles
10.1002/minf.201600043 · 2016 · External reference
10.1016/j.ymeth.2014.09.006
10.1016/j.ymeth.2014.09.006 · External reference
The challenges involved in modeling toxicity data in silico: a review
10.2174/138161212799436359 · 2012 · External reference
10.1016/j.jprot.2011.05.011
10.1016/j.jprot.2011.05.011 · External reference
Computational Approaches in Antibody-drug Conjugate Optimization for Targeted Cancer Therapy
10.2174/1568026618666180731165222 · 2018 · External reference
10.1016/j.csbj.2020.05.002 · Admitted local publication
10.1016/j.sbi.2020.05.016
10.1016/j.sbi.2020.05.016 · External reference
10.1021/acsomega.0c05303
10.1021/acsomega.0c05303 · External reference
10.1021/acs.jproteome.0c00779
10.1021/acs.jproteome.0c00779 · External reference
10.1007/s43440-020-00155-6
10.1007/s43440-020-00155-6 · External reference
Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal
10.1016/j.isci.2020.101697 · 2020 · External reference
10.1016/j.autrev.2020.102571
10.1016/j.autrev.2020.102571 · External reference
A comprehensive review on promising anti-viral therapeutic candidates identified against main protease from SARS-CoV-2 through various computational methods
10.1186/s43141-020-00085-z · 2020 · External reference
10.1517/17460441.2014.913565
10.1517/17460441.2014.913565 · External reference
10.1016/j.drudis.2019.02.004
10.1016/j.drudis.2019.02.004 · External reference
10.26434/chemrxiv.13643690.v1
10.26434/chemrxiv.13643690.v1 · External reference
10.1080/17460441.2020.1767063
10.1080/17460441.2020.1767063 · External reference
10.1021/acs.jmedchem.8b01610
10.1021/acs.jmedchem.8b01610 · External reference
High-resolution mining of the SARS-CoV-2 main protease conformational space: supercomputer-driven unsupervised adaptive sampling
2021 · External reference
Unresolved reference
External reference
10.1038/s41573-019-0050-3
10.1038/s41573-019-0050-3 · External reference
Integration of AI and traditional medicine in drug discovery
2021 · External reference
10.1016/j.drudis.2020.12.009
10.1016/j.drudis.2020.12.009 · External reference
The past, present and future of RNA respiratory viruses: influenza and coronaviruses
10.1093/femspd/ftaa046 · 2020 · External reference
Chemical Space: Big Data Challenge for Molecular Diversity
10.2533/chimia.2017.661 · 2017 · External reference
Riboswitches as Drug Targets for Antibiotics
2021 · External reference
10.1038/s41587-021-00841-7
10.1038/s41587-021-00841-7 · External reference
10.3389/fchem.2020.00343
10.3389/fchem.2020.00343 · External reference
Application of Negative Design To Design a More Desirable Virtual Screening Library
10.1021/acs.jmedchem.9b01476 · 2020 · External reference
Exploring novel and potent cell penetrating peptides in the proteome of SARS-COV-2 using bioinformatics approaches
10.1371/journal.pone.0247396 · 2021 · External reference
Three-dimensional pharmacophore methods in drug discovery
10.1021/jm900817u · 2010 · External reference
Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering
10.1016/j.jmgm.2007.11.005 · 2008 · External reference
The Pharmacophore Concept and Its Applications in Computer-Aided Drug Design
2019 · External reference
Similarity searching using 2D structural fingerprints
10.1007/978-1-60761-839-3_5 · 2011 · External reference
10.1038/nature14539
10.1038/nature14539 · External reference
10.3390/ijms20184574
10.3390/ijms20184574 · External reference
Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery
2018 · External reference
10.1080/17460441.2019.1615435
10.1080/17460441.2019.1615435 · External reference
De novo Molecular Design with Generative Long Short-term Memory
10.2533/chimia.2019.1006 · 2019 · External reference
A Review on Applications of Computational Methods in Drug Screening and Design
2020 · External reference
10.3390/ijms22041676
10.3390/ijms22041676 · External reference
10.1111/cts.13007
10.1111/cts.13007 · External reference
Using DrugBank for In Silico Drug Exploration and Discovery
10.1002/cpbi.1 · 2016 · External reference
10.1021/acs.jcim.0c00675
10.1021/acs.jcim.0c00675 · External reference
Covalent Docking in Drug Discovery: Scope and Limitations
10.2174/1381612824999201105164942 · 2020 · External reference
Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications
10.1208/s12248-018-0216-7 · 2018 · External reference
New machine learning and physics-based scoring functions for drug discovery
10.1038/s41598-021-82410-1 · 2021 · External reference
High-Throughput Docking Using Quantum Mechanical Scoring
10.3389/fchem.2020.00246 · 2020 · External reference
In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking
10.1002/minf.202000115 · 2021 · External reference
Application of MM-PBSA Methods in Virtual Screening
2020 · External reference
ASFP (Artificial Intelligence based Scoring Function Platform): a web server for the development of customized scoring functions
10.1186/s13321-021-00486-3 · 2021 · External reference
10.1101/2020.11.04.369041
10.1101/2020.11.04.369041 · External reference
10.26434/chemrxiv.12915779.v1
10.26434/chemrxiv.12915779.v1 · External reference
10.1093/bib/bbaa034
10.1093/bib/bbaa034 · External reference
Artificial intelligence for COVID-19 drug discovery and vaccine development
10.3389/frai.2020.00065 · 2020 · External reference
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research
2020 · External reference
10.1016/j.virusres.2020.198146
10.1016/j.virusres.2020.198146 · External reference
10.1021/acs.jcim.0c00491
10.1021/acs.jcim.0c00491 · External reference
Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages
10.1016/j.ejps.2020.105495 · 2020 · External reference
A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro
10.1371/journal.pcbi.1008489 · 2020 · External reference
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches
10.1016/j.meegid.2020.104451 · 2020 · External reference
Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19
10.1021/acsptsci.0c00131 · 2020 · External reference
10.1016/j.drup.2020.100719
10.1016/j.drup.2020.100719 · External reference
Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review
10.1007/s11130-020-00861-9 · 2020 · External reference
HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19
10.1126/sciimmunol.abc5367 · 2020 · External reference
QSAR Modeling of SARS-CoV M(pro) Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2
10.1002/minf.202000113 · 2021 · External reference
Bepridil is potent against SARS-CoV-2 in vitro
2021 · External reference
10.1038/s41586-020-2223-y
10.1038/s41586-020-2223-y · External reference
10.1021/acsptsci.0c00130
10.1021/acsptsci.0c00130 · External reference
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
10.1126/science.abb4489 · 2020 · External reference
10.1101/2020.08.28.271957
10.1101/2020.08.28.271957 · External reference
10.3390/ijms21113793
10.3390/ijms21113793 · External reference
10.1021/acs.jpclett.0c02421
10.1021/acs.jpclett.0c02421 · External reference
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
10.1016/s0140-6736(20)30304-4 · 2020 · External reference
10.15252/emmm.202012817
10.15252/emmm.202012817 · External reference
10.1016/j.bcp.2020.114169
10.1016/j.bcp.2020.114169 · External reference
10.15252/emmm.202012697
10.15252/emmm.202012697 · External reference
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality
10.1126/sciadv.abe4724 · 2021 · External reference
10.1172/jci89857
10.1172/jci89857 · External reference
10.1038/s41598-018-25640-0
10.1038/s41598-018-25640-0 · External reference
The Emerging Role of Artificial Intelligence in the Fight Against COVID-19
10.1016/j.eururo.2020.09.031 · 2020 · External reference
10.1038/s41591-020-0916-2
10.1038/s41591-020-0916-2 · External reference
10.1016/j.isci.2020.101642
10.1016/j.isci.2020.101642 · External reference
10.1101/2020.07.27.223578
10.1101/2020.07.27.223578 · External reference
10.1016/j.compbiolchem.2020.107408
10.1016/j.compbiolchem.2020.107408 · External reference
10.1093/database/bay016
10.1093/database/bay016 · External reference
10.1101/2020.05.27.117184
10.1101/2020.05.27.117184 · External reference
10.1128/aac.00872-20
10.1128/aac.00872-20 · External reference
10.1016/j.ijbiomac.2020.07.235
10.1016/j.ijbiomac.2020.07.235 · External reference
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
10.1126/science.abd9909 · 2020 · External reference
Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges
10.1080/17460441.2021.1854221 · 2021 · External reference
A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals
10.1186/s12967-020-02476-9 · 2020 · External reference
Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions
10.1016/j.drudis.2020.12.010 · 2021 · External reference
10.1038/s41591-019-0670-5
10.1038/s41591-019-0670-5 · External reference
Bringing together the academic drug discovery community
10.1038/nrd4155 · 2013 · External reference
10.1038/nrd.2017.217
10.1038/nrd.2017.217 · External reference
10.1111/cts.12531
10.1111/cts.12531 · External reference
Rethinking 'academic' drug discovery: the Manchester Institute perspective
10.1016/j.drudis.2014.12.011 · 2015 · External reference
Academic drug discovery within the United Kingdom: a reassessment
10.1038/nrd4661 · 2015 · External reference
Institutional profile: the national Swedish academic drug discovery & development platform at SciLifeLab
10.4155/fsoa-2017-0013 · 2017 · External reference
10.1080/17460441.2019.1553952
10.1080/17460441.2019.1553952 · External reference
Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study
10.1016/s2214-109x(20)30264-3 · 2020 · External reference
